Anti-BTN3a antibodies and their use in treating cancer or infectious disorders
Patent Information
- Application Number
- HK42026122969
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-01-28
- Filing Date
- 2026-05-07
- Publication Date
- 2026-07-31
AI Technical Summary
There is a lack of effective antibodies for the treatment of cancer and infectious diseases in the current technology, especially specific binding antibodies against BTN3A.
Develop humanized antibodies, particularly those targeting BTN3A, for the treatment of cancer and infectious diseases.
It has enabled effective treatment of cancer and infectious diseases, especially through the specific binding of BTN3A, which has improved treatment efficacy.
Smart Images
Figure 00000055_0000 
Figure 00000055_0001 
Figure 00000055_0002
Abstract
Description
(19) *EP004650007A3* (11) EP 4 650 007 A3 (12) EUROPEAN PATENT APPLICATION (88) Date of publication A3: 25.02.2026 Bulletin 2026 / 09 (43) Date of publication A2: 19.11.2025 Bulletin 2025 / 47 (21) Application number: 25206189.0 (22) Date of filing: 31.07.2019 (51) International Patent Classification (IPC): C07K 16 / 28 (2006.01) (52) Cooperative Patent Classification (CPC): C07K 16 / 2827; A61K 39 / 39541; A61K 40 / 11; A61K 40 / 421; A61P 35 / 00; A61P 35 / 02; A61K 2039 / 54; A61K 2039 / 545; A61K 2239 / 31; A61K 2239 / 38; A61K 2239 / 48; A61K 2239 / 49; A61K 2239 / 50; A61K 2239 / 58; A61K 2239 / 59; (Cont.) (84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (30) Priority: 01.08.2018 EP 18306050 28.01.2019 EP 19153992 (62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC: 19745618.9 / 3 830 119 (71) Applicants: • Imcheck Therapeutics 13009 Marseille 9e Arrondissement (FR) • Institut National de la Sante et de la Recherche Medicale (INSERM) 75013 Paris (FR) • Aix-Marseille Université 13284 Marseille Cedex 07 (FR) • Institut Jean Paoli & Irène Calmettes 13009 Marseille (FR) • Centre National de la Recherche Scientifique - CNRS - Etablissement Public, Scientifique et Technologique (EPST) 75018 Paris (FR) (72) Inventors: • TRUNEH, Alemseged Massachusetts 01776 (US) • OLIVE, Daniel 13009 Marseille (FR) • PASERO, Christine 13009 Marseille (FR) • DE GASSART, Aude 13009 Marseille (FR) (74) Representative: Plasseraud IP 104 Rue de Richelieu CS92104 75080 Paris Cedex 02 (FR) (54) ANTI‑BTN3A ANTIBODIES AND THEIR USE IN TREATING CANCER OR INFECTIOUS DISORDERS (57) The present invention relates to humanized antibodies that specifically bind to human BTN3A and their use in treating cancer and infectious disorders. EP 4 65 0 00 7 A 3 Processed by Luminess, 75001 PARIS (FR) (Cont. next page) (52) Cooperative Patent Classification (CPC): (Cont.) C07K 2317 / 24; C07K 2317 / 33; C07K 2317 / 55; C07K 2317 / 73; C07K 2317 / 75; C07K 2317 / 92; C07K 2317 / 94 2 EP 4 650 007 A3 3 EP 4 650 007 A3 5 10 15 20 25 30 35 40 45 50 55 4 EP 4 650 007 A3 5 10 15 20 25 30 35 40 45 50 55 5 EP 4 650 007 A3 5 10 15 20 25 30 35 40 45 50 55 6 EP 4 650 007 A3 5 10 15 20 25 30 35 40 45 50 55 7 EP 4 650 007 A3 5 10 15 20 25 30 35 40 45 50 55 摘要 本发明涉及与人 BTN3A 特异性结合的人源化抗体及其在治疗癌症和 感染性病症中的用途。
Claims
1. An isolated anti-BTN3A antibody for use in treating hematological malignancy in a human subject in need thereof, wherein said anti-BTN3A antibody comprises a heavy chain of SEQ ID NO:4 and a light chain of SEQ ID NO:
6. [Page 4, lines 3-10 and Page 28, lines 8-12]2. An isolated anti-BTN3A antibody for use according to Claim 1, wherein said hematological malignancy is acute myeloid leukemia. Page 28, lines 8-123. A host cell for expressing an anti-BTN3A antibody having a heavy chain of SEQ ID NO:4 and a light chain of SEQ ID NO:6, said host cell comprising the nucleic acids of SEQ ID NO:8 and 10. Page 19 last paragraph and Page 20, lines 10-114. A host cell of Claim 3, which is a mammalian host cell. Page 19 last paragraph and Page 20, lines 10-11